GLP2-TRZ 30mg

Tirz 30mg — Research Peptide

Contains:

• Tirz 30mg

Class: Synthetic dual agonist peptide studied in incretin signaling pathways (GLP-1 / GIP receptor activity) and metabolic regulation models

Research Focus (non-clinical):
• GLP-1 and GIP receptor pathway interactions and downstream signaling activity
• Glucose metabolism and insulin-response signaling in experimental models
• Appetite-regulation pathways and neuroendocrine signaling mechanisms
• Lipid metabolism and adipocyte function in metabolic research settings
• Gastrointestinal motility and gastric-emptying pathway investigations
• Energy-balance and weight-regulation signaling in preclinical studies

Notes for Investigators:
Tirzepatide is a synthetic peptide engineered to act as a dual agonist at both GLP-1 (glucagon-like peptide-1) and GIP (glucose-dependent insulinotropic polypeptide) receptors. In laboratory research, this dual-incretin mechanism is investigated for its effects on metabolic signaling, including insulin secretion pathways, glucagon modulation, and nutrient-response dynamics.

Preclinical models frequently examine tirzepatide’s influence on endocrine signaling networks involved in glucose homeostasis, appetite regulation, and energy utilization. Its dual-receptor activity distinguishes it from single-pathway incretin analogs, making it a subject of interest in studies exploring integrated metabolic control, adipose tissue signaling, and coordinated hormonal responses.

Tirzepatide provides a high-concentration, single-vial format for researchers investigating incretin-based signaling systems and metabolic pathway interactions under controlled experimental conditions.

Regulatory & Use:
Laboratory research only. Not for human or veterinary use. Intended strictly for in vitro and preclinical research applications.